



## MEDICAL TIPS

### TENEBLU TABLETS

Issue VIII, No. 29, 2023

### **Teneligliptin Observational Retrospective Real-World Study to Evaluate Its Effect on Renal Parameters and Safety in Indian Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease (TOP RENAL).**

*Suryawanshi S et al. Diabetes 2023; 72(1): 16-LB.*

- Teneligliptin is the most commonly prescribed DPP4i in India and hence a real world study (TOP RENAL study) was conducted to evaluate the effects of teneligliptin on renal parameters and safety in Indian T2DM patients with CKD .
- The study enrolled 377 patients that were grouped based on their eGFR (ml/min/1.73m<sup>2</sup>) of 45-59 (n=102), 30-44 (n=124) and 15-29 (n=151).
- The renal parameters of eGFR, serum creatinine and BUN were assessed at baseline, 3 months and 6 months.
- No significant changes were observed in the renal parameters in all the three groups and no safety concerns or hypoglycaemia episodes were reported.

**Teneligliptin initiation in Indian T2DM patients with mild-severe renal impairment did not show any safety concerns and was well tolerated.**

